Donor resourcing
The Global Fund to fight AIDS, TB and Malaria, Grant Cycle 8, 2026 – 2028
The Global Fund to fight AIDs, TB and Malaria (GFATM) policies have increasingly evolved to enable countries to integrate viral hepatitis services into HIV programmes for people living with HIV, key populations and pregnant women. Many countries were able to leverage this opportunity in the current Grant Cycle (GC7, 2023 – 2025).
However, recent global aid shortfalls have reduced Global Fund allocations for the remainder of GC7. This has forced countries to reprioritise activities which can create both risks and opportunities for hepatitis.
The current GC7 reprioritisation process and the upcoming Grant Cycle 8 (GC8, 2026 – 2028) are key opportunities for hepatitis communities to advocate for the sustained inclusion of hepatitis interventions in Global Fund-supported programming.
To help equip advocates to engage in the Global Fund’s reprioritisation efforts in GC8, the Clinton Health Access Initiative (CHAI) and WHA have partnered to develop a new briefing to support communities advocate effectively for the integration and long-term sustainability of hepatitis interventions within Global Fund-supported programmes, primary health care and community systems.
Global Fund Grant Cycle 7, 2023 – 2025
CHAI together with support from partners including the World Hepatitis Alliance, World Health Organization and others developed a Resource Toolkit on GFATM 2023 – 2025 Funding Opportunity for Hepatitis to equip a wide range of stakeholders to understand the GFATM hepatitis-related policies and support advocacy efforts for hepatitis services. While the Global Fund will enter a new grant cycle in 2026, this resource still has information that is relevant to advocates that are looking to better understand Global Fund processes.
Based on the previous Global Fund Grant Cycle 7 (GC7, 2023 – 2025), the toolkit includes:
- A detailed summary of the evolution of GFATM hepatitis-related policies and specific guidance for the 2023-2025 funding round
- Several Country Case Studies, highlighting countries who have been successful in this process
- Tools to support advocacy and funding requests like the rationale for making hepatitis-related investments, cost-effectiveness rationale, a summary of pricing for hepatitis B and C commodities, generic advocacy workplan and activities checklist that can be customized to country settings
- …and much more!
WHA also developed a short brief to advocates to complement the more detailed toolkit.
Webinar
On Tuesday 13 December 2022, WHA hosted a webinar to discuss the opportunities for countries to include hepatitis programmes in their proposals. Speakers also previewed the resource toolkit developed by CHAI and other partners, to support stakeholders to navigate the GFATM policies and processes.
Watch it here ➡️